Related Experiment Videos
Ifosfamide vs cyclophosphamide in cancer therapy
1Uniformed Services University of the Health Sciences, Bethesda, MD.
Oncology (Williston Park, N.Y.)
|May 1, 1991
Summary
Ifosfamide, a cyclophosphamide analog, shows similar anticancer activity but is not proven superior. Cyclophosphamide remains the preferred oxazaphosphorine for most cancers due to ifosfamide
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Cyclophosphamide is a long-established, effective oxazaphosphorine chemotherapy agent.
- Ifosfamide is a newer analog with similar antitumor activity but different pharmacokinetics.
Purpose of the Study:
- To compare the efficacy and toxicity of ifosfamide versus cyclophosphamide.
- To determine the optimal oxazaphosphorine analog for treating malignancies.
Main Methods:
- Pharmacokinetic analysis of ifosfamide and cyclophosphamide.
- Review of clinical data on efficacy and toxicity in various cancers.
- Cost-effectiveness and patient convenience assessment.
Main Results:
- Ifosfamide has not demonstrated superiority over cyclophosphamide in any cancer.
- Ifosfamide exhibits a less favorable toxicity profile and higher costs.
- Current approved uses for ifosfamide include metastatic testicular carcinoma and sarcomas.
Conclusions:
- Cyclophosphamide remains the preferred choice for most malignancies responsive to oxazaphosphorines.
- Ifosfamide's advantages in efficacy are not yet proven, while its disadvantages in toxicity and cost are evident.